| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jan 11, 2016- Expects full-year 2016 adjusted earnings per diluted share to be in a range of $9.50 to $10.10, an increase of 24% to 29% over 2015 adjusted earnings per diluted share guidance range of $7.65 to $7.85
Perrigo Company plc (NYSE: PRGO; TASE) today increased full-year 2016 adjusted earnings per diluted share guidance to be in a range of $9.50 to $10.10, up from the Company's October 22, 2015...
-
Jan 4, 2016
Allergan plc (NYSE: AGN) and its partner Perrigo Company plc (NYSE: PRGO; TASE) announced the launch of combination guaifenesin 600mg and pseudoephedrine HCl 60mg extended-release tablets to...
-
Dec 29, 2015
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Perrigo Chairman and CEO Joseph Papa will present at the 34th Annual J.P. Morgan Healthcare Conference at 8:00 AM PST on Monday, January...
-
Dec 17, 2015- Acquires unique assets that fit well within Perrigo's Rx extended topicals portfolio
Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) announced today that it will acquire a portfolio of generic dosage forms and strengths of Retin-A® (tretinoin) from Matawan Pharmaceuticals,...
-
Nov 23, 2015- Expands Perrigo's Rx extended topicals portfolio to include well-established gastrointestinal product and brand
Perrigo Company plc ("Perrigo") (NYSE: PRGO; TASE) announced today that it will acquire Entocort® (budesonide) capsules as well as the authorized generic capsules marketed by Par Pharmaceuticals...